Peptide Decoding
News

Does Switching From Semaglutide to Tirzepatide Help? What 20,486 Records Show

By Allison Thorne · Editorial standards
Published November 19, 2026
Two glass vials side by side on a lit white surface, one empty and one holding pale teal liquid.

People who switched between semaglutide and tirzepatide were down an average of 16.0% of their body weight after two years, against 10.9% for people who stayed on the drug they started, in a Cleveland Clinic study presented at ObesityWeek on November 15, 2026.12 The study read the health records of 20,486 adults. It did not assign anyone to switch, and only about 2.7% of its assignments were switches.1

So the 16% describes a small group of people who chose to switch and then stuck with it. It does not show that switching caused the extra loss. The detail in the coverage that matters more is the direction of the switch. Moving from semaglutide to tirzepatide was linked to about 6.6 pounds more loss than staying on semaglutide, while moving the other way was linked to less.3 That lines up with the one head-to-head trial of the two drugs, where tirzepatide beat semaglutide.4

The more reassuring finding concerns stopping. People who stopped with nothing to replace the drug were still about 4% below their starting weight at two years.1

What did the Cleveland Clinic study find?

The study found that every path except stopping outright was linked to more weight loss over two years, and that surgery was linked to the most. Lead author Hamlet Gasoyan presented it at ObesityWeek, the Obesity Society's annual meeting, and the paper is published in eClinicalMedicine, a journal from the Lancet group.123

What people did after their first 90 days Share of assignments Weight change at 1 year At 2 years, paper At 2 years, conference abstract
Bariatric surgery 0.9% -21.8% -28.2% (69.4 lb) -26.6%
Switched between semaglutide and tirzepatide 2.7% -11.3% -16.0% (39.7 lb) -16%
Stayed on the starting drug 84.8% -10.0% -10.9% (27.1 lb) -10.9%
Switched to another obesity drug 2.6% -6.0% -8.2% (20.3 lb) -8.1%
Stopped with no replacement 9.0% -4.0% -4.0% (9.9 lb) -3.9%

The paper's figures come through a reproduction of the published article, and the conference figures come from Healio's report of the presentation.13 The two versions differ slightly, most on surgery, and we print both. Cleveland Clinic's own release rounds the surgery figure to 28%, closer to the paper.2

Everyone in the study had taken semaglutide or tirzepatide for at least 90 days, starting between January 2021 and December 2023 at Cleveland Clinic sites in Ohio and Florida, and was followed to the end of 2025.1 About three in four started on semaglutide, 63% were women, the average age was 56.7, and about two-thirds had type 2 diabetes.5

Is switching to tirzepatide better than staying on semaglutide?

In this study, people who moved from semaglutide to tirzepatide lost about 3 kg, or 6.6 pounds, more over two years than people who stayed on semaglutide.3 People who started on tirzepatide and stayed on it lost about 4.5 kg, or 9.9 pounds, more than people who moved from tirzepatide to semaglutide.3

Read together, those two comparisons suggest that the drug people ended on mattered more than the act of switching. The 16% figure for switchers mixes both directions, and the summaries we could read do not split it by direction.13 Since most people started on semaglutide, the switch group is likely weighted toward moves onto tirzepatide, though that is our inference and not something the paper states.

A randomized trial already answers the head-to-head question. In SURMOUNT-5, 751 adults with obesity and without diabetes took tirzepatide or semaglutide for 72 weeks. Weight fell 20.2% on tirzepatide and 13.7% on semaglutide.4 Our semaglutide vs tirzepatide comparison sets out the rest of that trial. The Cleveland Clinic records are consistent with it, at a smaller gap, in an older and mostly diabetic group.

Why can't this study prove switching works?

It cannot, because nobody chose their path at random, and the people who switched or had surgery may differ from the rest in ways the records do not show. The authors say plainly that the findings are associations and need confirmation in a study that assigns strategies in advance.1

The method they used, called target trial emulation, is a careful one. It sets up the comparison as if it were a trial, using health records, and then weights each group to balance 38 measured traits such as age, weight and diagnoses.1 That reduces some bias. It cannot balance what was never recorded, and Medical Daily's write-up lists insurance, income, how well someone tolerated side effects and support at home as examples.5

The analysis was also per-protocol. It follows people who kept to a strategy and sets aside anyone who drifted from it, so a person who switched, felt sick and stopped two months later drops out of the switch group.15 That flatters any strategy people find hard to keep up. The authors add that, in real life, people often stop because of cost, shortages or side effects. A per-protocol model sets those reasons aside and estimates what would happen if everyone had kept going.1

What happened to people who stopped?

They kept most of what they had lost. People who stopped with no replacement were 4.0% below their starting weight at one year and still 4.0% at two years.1 That is far less regain than the withdrawal trials found. In STEP 1's extension, people regained about two-thirds of their loss within a year of stopping semaglutide, and our guide to stopping semaglutide or tirzepatide explains why trial and real-world regain numbers differ so much.6

The same team found something similar in March 2026. In 7,938 adults who stopped within 3 to 12 months, people with obesity had lost 8.4% before stopping and regained an average of 0.5% over the following year.7 Many of those people did not stay untreated. Within a year, 19.6% had restarted the same drug and 35.2% had started another obesity treatment.6

Real-world patients also lose less on the drug than trial patients do. The 10.9% for people who stayed on their starting drug is roughly half what tirzepatide produced in SURMOUNT-5.14 Diabetes may be part of the reason. In the March study, people taking the drugs for type 2 diabetes had lost 4.4% before stopping, against 8.4% for people taking them for obesity.7

One early event was linked to stopping. An emergency department visit in the first 90 days raised the odds of discontinuing 1.78-fold.1 Early emergency visit rates were similar on the two drugs, 26.88 per 100 person-years on semaglutide and 25.05 on tirzepatide. Person-years count the total time everyone spent in the study, so the figure is a rate, not a share of people.1

What did the study not measure?

It did not capture compounded drugs or other off-label supply, according to the authors' own list of limitations.1 Diet changes, heart events and long-term kidney outcomes were also not systematically recorded.1

The first gap matters for this site's readers. Someone who left a pharmacy prescription for a compounded or gray-market vial would, as far as these records could show, look like someone who stopped. If enough people did that, the stopped group would look better than true stopping does. The study cannot say how many did.

What does this change for someone with a vial?

The study says nothing about gray-market vials, because it followed prescriptions inside one health system. What it does add is a real-world signal pointing the same way as the head-to-head trial: on average, tirzepatide was linked to more loss than semaglutide.34

Both drugs are widely sold outside pharmacies. Our November 15 price read found tirzepatide at 174 vendors across 613 listings, with 10 mg vials at $36.99 to $100.00 across 107 stores. Semaglutide was at 141 vendors across 337 listings, with 10 mg vials at $35.00 to $129.90 across 91 stores.8

A switch is not one injection replacing another. Both drugs stay in the body for weeks after the last dose, so the old drug is still active when the new one starts, and our guide to switching and stacking GLP-1s explains how that overlap can look like poor tolerance of the new drug.9 Retatrutide was not part of this study, since it is not approved anywhere.8

The careful version of a switch looks the same as any purchase: a per-lot certificate of analysis with the lot number printed on the vial, a seller on our vendor list with no open FDA warning letter, an independent test of the first vial, and the dose calculator run on the concentration the test actually found.

What happens next?

The authors say the next step is prospective confirmation, meaning a study that sets the strategies before anyone starts.1 Until one exists, this paper is the largest real-world comparison of what people did after their first three months on these drugs, and SURMOUNT-5 remains the randomized test of the two drugs against each other.14

The study's own lead author framed the practical point around staying in treatment. In Healio's report, Gasoyan said: "Our study highlights the importance of continued obesity management."3

Common questions

Does switching from semaglutide to tirzepatide cause more weight loss?

Not proven. In the Cleveland Clinic records, people who switched from semaglutide to tirzepatide lost about 6.6 pounds more over two years than people who stayed on semaglutide, but the study was observational and nobody was assigned to switch.

How much weight did switchers lose?

An average of 16.0% of body weight at two years, about 39.7 pounds, against 10.9% for people who stayed on their starting drug. Those are per-protocol figures, counting people who kept to the strategy.

What about switching from tirzepatide to semaglutide?

It was linked to less loss. People who stayed on tirzepatide lost about 9.9 pounds more over two years than people who moved from tirzepatide to semaglutide.

Is tirzepatide stronger than semaglutide?

In the one head-to-head trial, yes on weight. SURMOUNT-5 found 20.2% weight loss on tirzepatide and 13.7% on semaglutide after 72 weeks in adults with obesity and without diabetes.

How many people in the study switched?

Few. About 2.7% of the study's assignments were switches between the two drugs, against 84.8% who stayed on their starting drug and 9.0% who stopped.

Do you regain all the weight after stopping a GLP-1?

Not in this study. People who stopped with no replacement were still about 4% below their starting weight at two years. Withdrawal trials found much more regain, and the reasons differ by study.

Why is this different from the trials where people regained weight?

Trials switch everyone to placebo on a set date. Real-world patients stop at different points, often after losing less, and many restart or move to another treatment within a year.

Did the study include compounded or gray-market drugs?

No. The authors say compounded drugs and other off-label supply were not captured. Someone who moved to a non-pharmacy vial would look like someone who stopped.

Did the study include retatrutide?

No. Retatrutide is not approved anywhere, so it does not appear in prescription records.

Which strategy was linked to the most weight loss?

Bariatric surgery, at 28.2% of body weight after two years in the published paper and 26.6% in the conference abstract. Very few people, about 0.9% of assignments, took that path.

What is target trial emulation?

A way of analyzing health records as if they came from a trial, by defining who is eligible, what each group did and when follow-up starts, then weighting groups to balance their measured traits. It reduces bias but cannot replace randomization.

What does per-protocol mean here?

The analysis followed people who kept to their strategy and set aside those who drifted from it. That tends to favor strategies people find hard to stick with.

Who ran the study?

Researchers at Cleveland Clinic, led by Hamlet Gasoyan. It used Cleveland Clinic patient records from Ohio and Florida.

Was it published?

Yes, in eClinicalMedicine in November 2026, according to Cleveland Clinic and a summary of the paper. One news report described it only as a conference presentation, so the two accounts disagree.

Did the study find a safety difference between the drugs?

Not in emergency visits. Early emergency department visit rates were similar, 26.88 per 100 person-years on semaglutide and 25.05 on tirzepatide.

Can you start tirzepatide the day after your last semaglutide dose?

The study did not test timing. Both drugs stay in the body for weeks, so the two overlap after a switch, and that overlap can feel like poor tolerance of the new drug.

Sources

  1. Gasoyan H, et al. Weight maintenance after discontinuation of GLP-1 therapies. eClinicalMedicine, 2026, article 104321. doi:10.1016/j.eclinm.2026.104321. thelancet.com.
    Read via a reproduction: the journal page would not load (client error), so figures were read from Scienmag's summary of the paper, republished by Bioengineer.org on November 15, 2026 (bioengineer.org). Source of the cohort (30,514 initiators, 20,486 in the nested trials), the eligibility and follow-up dates, the strategy shares at assignment, the per-protocol weight changes at one and two years in kg and percent, the 38-covariate weighting, the clone-censor-weight method, the emergency visit rates and the 1.78-fold odds, and the authors' limitations, including that compounded and off-label drug use was not captured. The summary gives no confidence intervals. The article title is as the search result listed it and could differ in the final version. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
  2. Cleveland Clinic. Cleveland Clinic Study Identifies Best Treatment Strategies for Weight Loss After Stopping GLP-1 Drugs. November 14, 2026. newsroom.clevelandclinic.org.
    Read at source. The institution's own release about its own study, not independent confirmation. States the November 15 ObesityWeek presentation and publication in eClinicalMedicine, the 20,486 patients and the rounded two-year figures (surgery 28%, switching about 16%, continuing nearly 11%, another obesity drug about 8%, stopping about 4%). Gives no limitations. ↩ ↩ ↩
  3. Healio. Continued obesity treatment linked to long-term weight loss. November 14, 2026. healio.com.
    Read at source. Independent reporting on the ObesityWeek presentation (Gasoyan H, et al. Oral-021). Source of the conference figures (26.6%, 16%, 10.9%, 8.1%, 3.9%), the 3 kg and 4.5 kg directional comparisons, the description as target trial emulation with a per-protocol analysis, and the quoted Gasoyan sentence. Gives no confidence intervals. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
  4. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine, 2025;393(1):26-36. doi:10.1056/NEJMoa2416394.
    Read via a reproduction: the American College of Cardiology journal scan of July 10, 2025 (acc.org). Source of the SURMOUNT-5 design (751 adults with obesity and without diabetes, 72 weeks, maximum tolerated doses) and the 20.2% and 13.7% weight changes. The same figures appear on our comparison page. ↩ ↩ ↩ ↩ ↩
  5. Medical Daily. Switching GLP-1 drugs was linked to more weight loss than staying on the original medication, but the Cleveland Clinic data do not prove switching caused the difference. November 15, 2026. medicaldaily.com.
    Read at source. Independent reporting. Source of the baseline characteristics (73.4% started on semaglutide, 63% women, mean age 56.7, about two-thirds with type 2 diabetes) and the list of unmeasured differences. It describes the analysis as a conference presentation not yet in a journal, which conflicts with Cleveland Clinic's release and the paper summary; we treat the release and the summary as the stronger account, since both name the journal and the summary gives an article number. ↩ ↩ ↩
  6. Peptide Decoding. What Happens When You Stop Semaglutide or Tirzepatide? What the Regain Studies Measured. October 17, 2026. peptidedecoding.com/guides/glp1-weight-regain.
    Our own guide, read November 16, 2026. Source of the STEP 1 extension figures (17.3% loss at week 68 to 5.6% net at week 120, described by its authors as two-thirds regained) and of the March 2026 study's restart and switch shares (19.6% and 35.2%), each cited there to its primary paper. ↩ ↩
  7. Cleveland Clinic. What happens when patients stop taking GLP-1 drugs? New Cleveland Clinic study reveals real world insights. March 12, 2026, via EurekAlert. eurekalert.org.
    Read at source on EurekAlert. The institution's release about Gasoyan H, et al., Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide, Diabetes, Obesity and Metabolism, 2026, doi:10.1111/dom.70660. Source of the 7,938 adults, the 8.4% and 4.4% losses before stopping and the 0.5% average regain at one year in the obesity group. ↩ ↩
  8. Peptide Decoding. Tirzepatide and semaglutide compound pages, and the retatrutide compound page. peptidedecoding.com/peptides/tirzepatide, peptidedecoding.com/peptides/semaglutide, peptidedecoding.com/peptides/retatrutide.
    Our own data, read November 16, 2026. Price figures last read November 15, 2026: tirzepatide 174 vendors, 613 listings, 10 mg vials $36.99 to $100.00 across 107 stores; semaglutide 141 vendors, 337 listings, 10 mg vials $35.00 to $129.90 across 91 stores. Retatrutide is not approved anywhere. ↩ ↩
  9. Peptide Decoding. Can You Stack Tirzepatide and Retatrutide? What Labels Say. peptidedecoding.com/guides/stacking-glp1s.
    Our own guide, read November 16, 2026. Source of the point that semaglutide, tirzepatide and retatrutide have long half-lives, so a switch leaves both drugs active for weeks, and that the overlap can look like poor tolerance of the new drug. ↩

Citing this page. Peptide Decoding. Does Switching From Semaglutide to Tirzepatide Help? What 20,486 Records Show. Study figures from Gasoyan et al., eClinicalMedicine, and the ObesityWeek presentation of November 15, 2026; trial figures from SURMOUNT-5 (NEJM, 2025); price figures from our November 15, 2026 capture. Reviewed November 16, 2026. https://peptidedecoding.com/news/semaglutide-tirzepatide-switching-study